ATRA · ISSUER CIK 1604464
Atara Biotherapeutics, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 2 Atara Biotherapeutics, Inc. insiders reported $1000K of open-market purchases and $41K of sales on SEC Form 4. The largest buyer was Cherry Brian N (Director), with $1000K.
↗2 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 0 of 1 sales were reported under a 10b5-1 plan.
$1000KInsider buying
$41KInsider selling
+$959KNet open-market
Sep 4, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 202618:20 | Sep 4, 2026 | ATRA | Director | P · Buy | $9.60 | +104,166 | 166,486 | +167% | +$1000K | -17.6% | -9.8% |
| Aug 26, 202619:45 | Aug 17, 2026 | ATRA | President and CEO, Director | S · SellLate 9d | $8.08 | −5,062 | 132,775 | -4% | −$41K |